Skip to main content

Articles

Original Research, Practice Management
The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population
Nihar R. Desai, MD, MPH; Pamala Reed, DrPH, MPH; Paula J. Alvarez, RPh, MBA, MPH; Jeanene Fogli, PhD, RD; Steven D. Woods, PharmD; Mary Kay Owens, RPh, CPh
Stakeholder Perspective
The Impact of Quality Care on a Medicaid Population with Hyperkalemia
Byron C. Scott, MD, MBA
Read More
FDA Approvals
FDA Oncology Update
Read More
Perspectives
Predicting Success in Population Health
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS; Marlo Blazer, PharmD, BCOP; Lisa Bloudek, PharmD, MS; John Brokars, MS; Dinara Makenbaeva, MD, MBA
Stakeholder Perspective
The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs
James T. Kenney, RPh, MBA
Read More
Practice Management
Key Trends in Healthcare for 2020 and Beyond
F. Randy Vogenberg, PhD; John Santilli, MBA
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma
Read More
Page 44 of 244
Results 431 - 440 of 2440